Global Bipolar Disorder Therapeutics Market 2024-2028
The bipolar disorder therapeutics market is forecasted to grow by USD 787.02 mn during 2023-2028, accelerating at a CAGR of 2.68% during the forecast period. The report on the bipolar disorder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of bipolar disorder, advancements in drug development, and increasing holistic treatment approaches.
Technavio's bipolar disorder therapeutics market is segmented as below:
By Drug Class
- Antipsychotics
- Mood stabilizers
- Antidepressants
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increased prevalence of personalized treatment due to advances in genetics and neuroscience as one of the prime reasons driving the bipolar disorder therapeutics market growth during the next few years. Also, increasing global adoption of mental health services and increasing use of telemedicine and digital health tools will lead to sizable demand in the market.
The report on the bipolar disorder therapeutics market covers the following areas:
- Bipolar disorder therapeutics market sizing
- Bipolar disorder therapeutics market forecast
- Bipolar disorder therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bipolar disorder therapeutics market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Gedeon Richter Plc, GlaxoSmithKline Plc, H Lundbeck AS, Intra-Cellular Therapies Inc., Mallinckrodt Plc, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The London Psychiatry Centre, Wockhardt Ltd., and Zydus Lifesciences Ltd.. Also, the bipolar disorder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.